Last updated: February 20, 2026
Momeletinib dihydrochloride is an investigational drug primarily targeting cancer pathways. As a selective kinase inhibitor, it remains in development stages, and its supply chain is limited to specialized manufacturers involved in research and early-stage clinical trials.
How Many Suppliers Provide Momeletinib Dihydrochloride?
Currently, there are no publicly disclosed commercial manufacturing suppliers for momeletinib dihydrochloride. Its procurement occurs through specialized chemical synthesis companies or research institutes under confidentiality agreements for experimental or clinical use.
Key Characteristics of Supply Sources
| Supplier Type |
Description |
Typical Product Scope |
Regulatory Status |
| Research Chemical Suppliers |
Provide small quantities for research use, often in powder form |
Custom synthesis, pure grade for laboratory use |
Not approved for clinical or commercial sale |
| Contract Manufacturing Organizations (CMOs) |
May produce investigational quantities for clinical trials |
GMP-grade production under confidentiality |
Authorized for clinical trial supply, not commercial distribution |
| Academic or Government Labs |
Synthesize for internal research |
Experimental batches, often small-scale |
Not regulatory-approved |
Procurement Pathways
-
Custom Synthesis Firms: Limited to research-grade material for laboratory testing; some may produce GMP-grade for early clinical trials.
-
Specialized Chemical Vendors: Offer research chemicals that may include momeletinib dihydrochloride as a branded or generic compound, typically with limited documentation on purity and batch consistency.
-
Clinical Trial Supply Companies: For investigational new drug (IND) applications, supply is obtained through partnerships with licensed contract manufacturers capable of GMP compliance.
Market Availability Timeline
- Preclinical Phase: Typically involves academic and CRO-supplied material.
- Clinical Phase: Limited number of GMP-certified suppliers; often, manufacturing is contracted to select CMOs adhering to regulatory standards.
- Commercial Phase: Expected to involve larger pharmaceutical manufacturers, pending further drug approval.
Regulatory Considerations
As of Q1 2023, momeletinib dihydrochloride has not received regulatory approval for commercial sale. Its supply is restricted to clinical trial material with strict regulatory oversight.
Notable Companies Involved in Similar Kinase Inhibitor Supply
- Cambridge Isotope Laboratories: Specializes in research-grade chemicals, including kinase inhibitors for preclinical testing.
- WuXi AppTec: Offers custom synthesis and GMP manufacturing for investigational drugs.
- Lonza Group: Manufactures research chemicals and clinical supplies, including kinase inhibitors.
Summary
There are no fully commercial suppliers of momeletinib dihydrochloride. Its procurement occurs mainly through contract manufacturers and research chemical providers restricted to research and early-phase clinical settings. The drug is not available for general commercial purchase, reflecting its investigational status.
Key Takeaways
- No public commercial suppliers exist for momeletinib dihydrochloride.
- Industry involvement is limited to research-grade and GMP clinical trial manufacture.
- Supply channels are primarily contract manufacturing organizations and research chemical vendors.
- Availability is restricted to research and early clinical development.
- Regulatory approval and commercial manufacturing are pending further clinical progress.
FAQs
1. Can I purchase momeletinib dihydrochloride online for research purposes?
Yes, some chemical suppliers offer research-grade momeletinib dihydrochloride, but availability varies, and quality assurance is critical.
2. Does the supply of momeletinib dihydrochloride include GMP-certified batches?
Limited, mostly for clinical trial use; commercial-grade GMP supplies are not yet available.
3. Who qualifies as a supplier for GMP-grade momeletinib dihydrochloride?
Contract manufacturing organizations with regulatory approval to produce investigational drugs under Good Manufacturing Practice standards.
4. Are there regional restrictions on procurement?
Regulatory restrictions depend on local laws governing investigational drug importation and clinical trial conduct.
5. What is the typical lead time for obtaining momeletinib dihydrochloride for research?
Range varies from several weeks to months, depending on synthesis complexity and supplier capacity.
References
- U.S. Food and Drug Administration. (2023). Investigational New Drug Application Process.
- World Health Organization. (2022). Guidance on Good Manufacturing Practices for Investigational Medicinal Products.
- Chemical Abstracts Service. (2023). Data on kinase inhibitors synthesis and suppliers.
- ClinicalTrials.gov. (2023). Ongoing trials involving momeletinib.
- Pharmaceutical Technology. (2022). Contract manufacturing organizations' capabilities in phase I/II drug production.
